CoChat

Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial

Arnold, Lesley M., Hirsch, Ian, Sanders, Paul, Ellis, Amanda, Hughes, Bernadette · 2012 · Arthritis & Rheumatism
Cited by 40

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate the efficacy, tolerability, and safety of multiple fixed dosages of esreboxetine for the treatment of fibromyalgia. Methods: Patients meeting the American College of Rheumatology criteria for fibromyalgia were randomized to receive esreboxetine at dosages of 4 mg/day (n = 277), 8 mg/day (n = 284), or 10 mg/day (n = 283) or matching placebo (n = 278) for 14 weeks. The primary efficacy outcomes were the weekly mean pain score and the Fibromyalgia Impact Questionnaire (FIQ) total score at week 14. Secondary efficacy measures included scores for the Patient's Global Impression of Change (PGIC) scale, the Global Fatigue Index (GFI), and the 36‐item Short‐Form health survey (SF‐36; physical function scale only) at week 14. The safety profile of esreboxetine was evaluated based on adverse events and other safety measures. Results: Patients receiving all dosages of esreboxetine demonstrated statistically significant improvements in the pain score (P ≤ 0.025), the FIQ score (P ≤ 0.023), and the PGIC score (P ≤ 0.007) compared with patients in the placebo group. Additionally, patients receiving esreboxetine at dosages of 4 mg/day and 8 mg/day showed statistically significant improvements in the GFI score compared with those receiving placebo (P = 0.001). No significant differences in SF‐36 physical function scores were observed between patients receiving esreboxetine (any dosage) and those receiving placebo. Adverse events were mostly mild to moderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyperhidrosis, and palpitations were reported most frequently. Conclusion: Esreboxetine was generally well tolerated and was associated with significant improvements in pain, FIQ, PGIC, and fatigue scores compared with placebo. The lack of a dose‐response relationship in both the efficacy and safety analyses suggests that esreboxetine at a dosage of 4 mg/day would offer clinical benefit with the least risk of drug exposure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34390

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 40

Metadata

Authors
Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A., & Hughes, B.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-06-26
Volume
64
Issue
7
Pages
2387-2397
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2019759444
Cited by
40
References
10
FWCI
2.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial. https://app.cochat.ai/papers/10.1002/art.34390
The paper
Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A., & Hughes, B. (2012). Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen‐week, randomized, double‐blind, placebo‐controlled, multicenter clinical trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.34390

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.